Hervé Ghesquieres1, Susan L Slager1, Fabrice Jardin1, Amelie S Veron1, Yan W Asmann1, Matthew J Maurer1, Thierry Fest1, Thomas M Habermann1, Marie C Bene1, Anne J Novak1, Sylvain Mareschal1, Corinne Haioun1, Thierry Lamy1, Stephen M Ansell1, Herve Tilly1, Thomas E Witzig1, George J Weiner1, Andrew L Feldman1, Ahmet Dogan1, Julie M Cunningham1, Curtis L Olswold1, Thierry Jo Molina1, Brian K Link1, Noel Milpied1, David G Cox1, Gilles A Salles1, James R Cerhan2. 1. Hervé Ghesquieres, Universite Claude Bernard Lyon 1, Centre Leon Berard; Amelie S. Veron and David G. Cox, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Cancer Research Center of Lyon, Centre Leon Berard, Lyon; Hervé Ghesquieres and Gilles A. Salles, Faculté de Médecine Lyon-Sud; Gilles A. Salles, Universite Claude Bernard Lyon 1, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite; Fabrice Jardin, Sylvain Mareschal, and Herve Tilly, INSERM U918, Centre Henri Becquerel, Rouen; Thierry Fest, INSERM U917, Université de Rennes 1, Hopital Pontchaillou; Thierry Lamy, Université de Rennes 1, Hopital Pontchaillou, Rennes; Marie C. Bene, Centre Hospitalier Universitaire Nantes, Nantes; Corinne Haioun, Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) and University Paris Est, Créteil; Thierry Jo Molina, Universite Paris Descartes, AP-HP, Hôpital Necker, Paris; Noel Milpied, University Hospital and University of Bordeaux, Bordeaux, France; Hervé Ghesquieres, Susan L. Slager, Matthew J. Maurer, Thomas M. Habermann, Anne J. Novak, Stephen M. Ansell, Thomas E. Witzig, Andrew L. Feldman, Ahmet Dogan, Julie M. Cunningham, Curtis L. Olswold, and James R. Cerhan, Mayo Clinic, Rochester, MN; Yan W. Asmann, Mayo Clinic, Jacksonville, FL; and George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA. 2. Hervé Ghesquieres, Universite Claude Bernard Lyon 1, Centre Leon Berard; Amelie S. Veron and David G. Cox, L'Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Cancer Research Center of Lyon, Centre Leon Berard, Lyon; Hervé Ghesquieres and Gilles A. Salles, Faculté de Médecine Lyon-Sud; Gilles A. Salles, Universite Claude Bernard Lyon 1, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite; Fabrice Jardin, Sylvain Mareschal, and Herve Tilly, INSERM U918, Centre Henri Becquerel, Rouen; Thierry Fest, INSERM U917, Université de Rennes 1, Hopital Pontchaillou; Thierry Lamy, Université de Rennes 1, Hopital Pontchaillou, Rennes; Marie C. Bene, Centre Hospitalier Universitaire Nantes, Nantes; Corinne Haioun, Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP) and University Paris Est, Créteil; Thierry Jo Molina, Universite Paris Descartes, AP-HP, Hôpital Necker, Paris; Noel Milpied, University Hospital and University of Bordeaux, Bordeaux, France; Hervé Ghesquieres, Susan L. Slager, Matthew J. Maurer, Thomas M. Habermann, Anne J. Novak, Stephen M. Ansell, Thomas E. Witzig, Andrew L. Feldman, Ahmet Dogan, Julie M. Cunningham, Curtis L. Olswold, and James R. Cerhan, Mayo Clinic, Rochester, MN; Yan W. Asmann, Mayo Clinic, Jacksonville, FL; and George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA. cerhan.james@mayo.edu.
Abstract
PURPOSE: We performed a multistage genome-wide association study to identify inherited genetic variants that predict outcome in diffuse large B-cell lymphoma patients treated with immunochemotherapy. METHODS: We conducted a meta-analysis of two genome-wide association study data sets, one from the LNH2003B trial (N = 540), a prospective clinical trial from the Lymphoma Study Association, and the other from the Molecular Epidemiology Resource study (N = 312), a prospective observational study from the University of Iowa-Mayo Clinic Lymphoma Specialized Program of Research Excellence. Top single nucleotide polymorphisms were then genotyped in independent cohorts of patients from the Specialized Program of Research Excellence (N = 391) and the Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) -075 randomized trial (N = 294). We calculated the hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) using a log-additive genetic model with adjustment for age, sex, and age-adjusted International Prognostic Index. RESULTS: In a meta-analysis of the four studies, the top loci for EFS were marked by rs7712513 at 5q23.2 (near SNX2 and SNCAIP; HR, 1.39; 95% CI, 1.23 to 1.57; P = 2.08 × 10(-7)), and rs7765004 at 6q21 (near MARCKS and HDAC2; HR, 1.38; 95% CI, 1.22 to 1.57; P = 7.09 × 10(-7)), although they did not reach conventional genome-wide significance (P = 5 × 10(-8)). Both rs7712513 (HR, 1.49; 95% CI, 1.29 to 1.72; P = 3.53 × 10(-8)) and rs7765004 (HR, 1.47; 95% CI, 1.27 to 1.71; P = 5.36 × 10(-7)) were also associated with OS. In exploratory analyses, a two-single nucleotide polymorphism risk score was highly predictive of EFS (P = 1.78 × 10(-12)) and was independent of treatment, IPI, and cell-of-origin classification. CONCLUSION: Our study provides encouraging evidence for associations between loci at 5q23.2 and 6q21 with EFS and OS in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, suggesting novel biology and the potential contribution of host genetics to the prognosis of this aggressive malignancy.
PURPOSE: We performed a multistage genome-wide association study to identify inherited genetic variants that predict outcome in diffuse large B-cell lymphomapatients treated with immunochemotherapy. METHODS: We conducted a meta-analysis of two genome-wide association study data sets, one from the LNH2003B trial (N = 540), a prospective clinical trial from the Lymphoma Study Association, and the other from the Molecular Epidemiology Resource study (N = 312), a prospective observational study from the University of Iowa-Mayo Clinic Lymphoma Specialized Program of Research Excellence. Top single nucleotide polymorphisms were then genotyped in independent cohorts of patients from the Specialized Program of Research Excellence (N = 391) and the Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) -075 randomized trial (N = 294). We calculated the hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) using a log-additive genetic model with adjustment for age, sex, and age-adjusted International Prognostic Index. RESULTS: In a meta-analysis of the four studies, the top loci for EFS were marked by rs7712513 at 5q23.2 (near SNX2 and SNCAIP; HR, 1.39; 95% CI, 1.23 to 1.57; P = 2.08 × 10(-7)), and rs7765004 at 6q21 (near MARCKS and HDAC2; HR, 1.38; 95% CI, 1.22 to 1.57; P = 7.09 × 10(-7)), although they did not reach conventional genome-wide significance (P = 5 × 10(-8)). Both rs7712513 (HR, 1.49; 95% CI, 1.29 to 1.72; P = 3.53 × 10(-8)) and rs7765004 (HR, 1.47; 95% CI, 1.27 to 1.71; P = 5.36 × 10(-7)) were also associated with OS. In exploratory analyses, a two-single nucleotide polymorphism risk score was highly predictive of EFS (P = 1.78 × 10(-12)) and was independent of treatment, IPI, and cell-of-origin classification. CONCLUSION: Our study provides encouraging evidence for associations between loci at 5q23.2 and 6q21 with EFS and OS in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, suggesting novel biology and the potential contribution of host genetics to the prognosis of this aggressive malignancy.
Authors: Thomas Ernst; Joannah Score; Michael Deininger; Claire Hidalgo-Curtis; Peter Lackie; William B Ershler; John M Goldman; Nicholas C P Cross; Francish Grand Journal: Br J Haematol Date: 2011-02-01 Impact factor: 6.998
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: Krista Rombouts; Vinicio Carloni; Tommaso Mello; Sara Omenetti; Sara Galastri; Stefania Madiai; Andrea Galli; Massimo Pinzani Journal: Cancer Lett Date: 2013-01-29 Impact factor: 8.679
Authors: Paul A Northcott; David J H Shih; John Peacock; Livia Garzia; A Sorana Morrissy; Thomas Zichner; Adrian M Stütz; Andrey Korshunov; Jüri Reimand; Steven E Schumacher; Rameen Beroukhim; David W Ellison; Christian R Marshall; Anath C Lionel; Stephen Mack; Adrian Dubuc; Yuan Yao; Vijay Ramaswamy; Betty Luu; Adi Rolider; Florence M G Cavalli; Xin Wang; Marc Remke; Xiaochong Wu; Readman Y B Chiu; Andy Chu; Eric Chuah; Richard D Corbett; Gemma R Hoad; Shaun D Jackman; Yisu Li; Allan Lo; Karen L Mungall; Ka Ming Nip; Jenny Q Qian; Anthony G J Raymond; Nina T Thiessen; Richard J Varhol; Inanc Birol; Richard A Moore; Andrew J Mungall; Robert Holt; Daisuke Kawauchi; Martine F Roussel; Marcel Kool; David T W Jones; Hendrick Witt; Africa Fernandez-L; Anna M Kenney; Robert J Wechsler-Reya; Peter Dirks; Tzvi Aviv; Wieslawa A Grajkowska; Marta Perek-Polnik; Christine C Haberler; Olivier Delattre; Stéphanie S Reynaud; François F Doz; Sarah S Pernet-Fattet; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Wolfram Scheurlen; Charles G Eberhart; Michelle Fèvre-Montange; Anne Jouvet; Ian F Pollack; Xing Fan; Karin M Muraszko; G Yancey Gillespie; Concezio Di Rocco; Luca Massimi; Erna M C Michiels; Nanne K Kloosterhof; Pim J French; Johan M Kros; James M Olson; Richard G Ellenbogen; Karel Zitterbart; Leos Kren; Reid C Thompson; Michael K Cooper; Boleslaw Lach; Roger E McLendon; Darell D Bigner; Adam Fontebasso; Steffen Albrecht; Nada Jabado; Janet C Lindsey; Simon Bailey; Nalin Gupta; William A Weiss; László Bognár; Almos Klekner; Timothy E Van Meter; Toshihiro Kumabe; Teiji Tominaga; Samer K Elbabaa; Jeffrey R Leonard; Joshua B Rubin; Linda M Liau; Erwin G Van Meir; Maryam Fouladi; Hideo Nakamura; Giuseppe Cinalli; Miklós Garami; Peter Hauser; Ali G Saad; Achille Iolascon; Shin Jung; Carlos G Carlotti; Rajeev Vibhakar; Young Shin Ra; Shenandoah Robinson; Massimo Zollo; Claudia C Faria; Jennifer A Chan; Michael L Levy; Poul H B Sorensen; Matthew Meyerson; Scott L Pomeroy; Yoon-Jae Cho; Gary D Bader; Uri Tabori; Cynthia E Hawkins; Eric Bouffet; Stephen W Scherer; James T Rutka; David Malkin; Steven C Clifford; Steven J M Jones; Jan O Korbel; Stefan M Pfister; Marco A Marra; Michael D Taylor Journal: Nature Date: 2012-08-02 Impact factor: 49.962
Authors: Soo Kee Min; Young Ho Koh; Yunwoong Park; Hyo Jung Kim; Jinwon Seo; Hye-Rim Park; Seong Jin Cho; In Sun Kim Journal: Korean J Pathol Date: 2012-04-25
Authors: Morteza Bashash; Joseph M Connors; Randy D Gascoyne; Barbara Meissner; Johanna M Schuetz; Stephen Leach; Graham W Slack; Brian R Berry; Howard Hu; Laurie H Sehn; Angela R Brooks-Wilson; John J Spinelli Journal: Haematologica Date: 2017-02-02 Impact factor: 9.941
Authors: James R Cerhan; Brian K Link; Thomas M Habermann; Matthew J Maurer; Andrew L Feldman; Sergei I Syrbu; Carrie A Thompson; Umar Farooq; Anne J Novak; Susan L Slager; Cristine Allmer; Julianne J Lunde; William R Macon; David J Inwards; Patrick B Johnston; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Neil E Kay; George J Weiner; Thomas E Witzig Journal: Int J Epidemiol Date: 2017-12-01 Impact factor: 7.196
Authors: Fredrik Baecklund; Sara Ekberg; Richard Rosenquist; Johan Askling; Sandra Eloranta; Karin E Smedby Journal: Eur J Haematol Date: 2020-09-29 Impact factor: 2.997